EN PL
REVIEW PAPER
Certolizumab pegol in the treatment of rheumatoid arthritis
 
More details
Hide details
 
Online publication date: 2011-08-30
 
 
Reumatologia 2011;49(4):253-263
 
KEYWORDS
ABSTRACT
Recently a new drug inhibiting TNF, certolizumab pegol, has been produced and tested in numerous laboratory and clinical trials. Owing to pegylation (addition of polyethylene glycol to the Fab fragment of TNF neutralizing antibody) this molecule shows different properties in comparison to other TNF neutralizing drugs. The present paper describes similarities as well as differences in mechanisms of action, pharmacokinetics, metabolism, clinical efficacy, influence of radiological progression and safety of certolizumab in comparison to other biological drugs inhibiting TNF used for the treatment of patients with rheumatoid arthritis (Table I-III). The results of clinical trials revealed relatively fast response to certolizumab (Table II, Figure 1). In addition, it was possible to predict, with rather high probability, the long term efficacy of this drug, which may be important for pharmacoeconomics of the treatment.
 
REFERENCES (26)
1.
Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumour necrosis factor agents on transmembrane tumour necrosis factor alpha-expressing cells: comparison among inflkiximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-1257. .
 
2.
Wallis RS, Schluger NW. Pulmonary infectious complications of tumour necrosis factor blockade. Infect Dis Clin North Am 2010; 24: 681-692. .
 
3.
Clark M. Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today 2000; 21: 397-402.  .
 
4.
Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54: 531-545. .
 
5.
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-1332. .
 
6.
Cominelli F. Cytokine-based therapies for Crohn’s disease – new paradigms. N Engl J Med 2004; 351: 2045-2048. .
 
7.
Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009; 348: 36-41. .
 
8.
UCB Cimzia® Prescribing Information www.ucb.com/_up/ucb_ com_products/documents/CIMZIA%20FINAL%20%2018%20November%202009.pdf (Accessed June 2010). .
 
9.
Parton T, King L, van Aspeeren J, et al. Investigation of the distribution and elimination of the PEG component of certolizumab pegol in rats. J Crohn’s Colitis Suppl 2008; 2: 26. .
 
10.
Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41: 1133-1137. .
 
11.
Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-3329. .
 
12.
Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. .
 
13.
Osterhaus J, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific work productivity survey (WPS-RA). Arthritis Res Ther 2009; 11: R73. .
 
14.
Emery P, Smolen J, Kavanaugh A, et al. Combination therapy with certolizumab pegol plus methotrexate improves household productivity and daily activities in patients with active rheumatoid arthritis. Arthritis Rheum 2008; 58 (Suppl): 977. .
 
15.
Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-811. .
 
16.
Cimzia_ (certolizumab pegol): US prescribing information. Georgia: UCB, Inc. [online]. Available from URL: http://www. cimzia.com/crohnsdisease/ pdf/Prescribing_Information.pdf [Accessed 2009 May 14]. .
 
17.
Duggan ST, Keam SJ. Certolizumab pegol in rheumatoid arthritis. Biodrugs 2009; 23: 407-417. .
 
18.
Furst D. Certolizumab pegol-what role does this new TNF inhibitor have in the treatment of RA? Nature Clinical Practice Rheumatology. Published online 02.2009. .
 
19.
Keystone E, Curtis J, Fleischmann R, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol 2011; 38: 990-996. .
 
20.
Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 2011; 38: 835-845. .
 
21.
Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011; 2: CD007649. .
 
22.
Weinblatt M, Fleischmann R, Emery P, et al. Efficacy and safety of certolizumab pegol in a clinically representative population of patients (Pts) with active rheumatoid arthritis (RA): results of the REALISTIC Phase IIIb Randomized Controlled Study. Arthritis Rheum 2010; 62 (10 suppl): S752-753. .
 
23.
Smolen J, van Vollenhoven R, Kavanaugh A, et al. Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis (RA): 3-year data from the RAPID 2 Study. Arthritis Rheum 2010; 62 (10 suppl): S753. .
 
24.
Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010; Ann Rheum Dis 2011; 70 (Suppl 1): i2-i36. .
 
25.
Patel AM, Moreland LW. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Experts Rev Clin Immunol 2010; 6: 855-866. .
 
26.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review) Copyright 2011. The Cochrane Collaboration. John Wiley & Sons, Ltd.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top